bevacizumab,trifluridine tipiracil
taiho pharma,roche,otsuka
[]
breaking news: #gi23 for mcrc patients on 3rd line treatment. showed os increase with lonsurf and bevacizumab compared to lonsurf alone. congrats to and more importantly to patients and their families. 
CEO of the Colorectal Cancer Alliance